CSTL

Castle Biosciences Inc

Add to Watchlist

Advanced Chart

20.330

+0.24(1.195%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

20.440

Open

20.245

VWAP

20.24

Vol

62.91K

Mkt Cap

582.78M

Low

20.080

Amount

1.27M

EV/EBITDA(TTM)

16.32

Total Shares

27.61M

317.25M

EV/OCF(TTM)

5.08

P/S(TTM)

1.71

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

70.80M

-19.53%

72.28M

-16.25%

71.21M

-16.98%

Estimates Revision

The market is revising Upward the revenue expectations for Castle Biosciences, Inc. (CSTL) for FY2025, with the revenue forecasts being adjusted by 7.07% over the past three months. During the same period, the stock price has changed by 23.96%.

Revenue Estimates for FY2025

Revise Upward

+7.07%

In Past 3 Month

Stock Price

Go Up

+23.96%

In Past 3 Month

6 Analyst Rating

63.94% Upside

Wall Street analysts forecast CSTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 33.33 USD with a low forecast of 17.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

63.94% Upside

Current: 20.330

Low

17.00

Averages

33.33

High

40.00

63.94% Upside

Current: 20.330

Low

17.00

Averages

33.33

High

40.00

Scotiabank

Outperform

downgrade

$44 -> $40

2025-05-21

Reason

Scotiabank

Price Target

$44 -> $40

2025-05-21

downgrade

Outperform

Reason

Scotiabank lowered the firm's price target on Castle Biosciences to $40 from $44 and keeps an Outperform rating on the shares. The company raised its full year guidance despite DecisionDx-SCC no longer being reimbursed by Medicare and the discontinuation of IDgenetix, the analyst tells investors. The company remains on track to launch a therapy guidance test for atopic dermatitis by the end of 2025, the firm adds.

Baird

Catherine Ramsey

Buy

Maintains

$36 → $37

2025-02-28

Reason

Baird

Catherine Ramsey

Price Target

$36 → $37

2025-02-28

Maintains

Buy

Reason

Stephens & Co.

Mason Carrico

Buy

Reiterates

$41

2025-01-02

Reason

Stephens & Co.

Mason Carrico

Price Target

$41

2025-01-02

Reiterates

Buy

Reason

Stephens analysts presented the firm's 2025 Best Ideas list, which includes Valley National (VLY), CoStar Group (CSGP), Castle Biosciences (CSTL), Alignment Healthcare (ALHC), Privia Health (PRVA), Vulcan Materials (VMC), South State (SSB), Matson (MATX), Azenta (AZTA), Prog Holdings (PRG), Carvana (CVNA), Blueprint Medicines (BPMC), Truist Financial (TFC), Cognex (CGNX), Fiserv (FI), Hancock Whitney (HWC), SunOpta (STKL), Wingstop (WING), SM Energy (SM), The Andersons (ANDE) and Bank of Marin (BMRC).

Scotiabank

Sung Ji Nam

Buy

Maintains

$37 → $44

2024-11-06

Reason

Scotiabank

Sung Ji Nam

Price Target

$37 → $44

2024-11-06

Maintains

Buy

Reason

Lake Street

Thomas Flaten

Strong Buy

Maintains

$34 → $40

2024-11-05

Reason

Lake Street

Thomas Flaten

Price Target

$34 → $40

2024-11-05

Maintains

Strong Buy

Reason

Lake Street raised the firm's price target on Castle Biosciences to $40 from $34 and keeps a Buy rating on the shares. The firm, which notes that its 2025 revenue estimate is $267.3M, is raising its target after a Q3 beat to reflect better-than-expected testing volumes in several tests and multiple expansion.

Baird

Catherine Ramsey

Buy

Maintains

$37 → $39

2024-11-05

Reason

Baird

Catherine Ramsey

Price Target

$37 → $39

2024-11-05

Maintains

Buy

Reason

Baird analyst Catherine Ramsey Schulte raised the firm's price target on Castle Biosciences to $39 from $37 and keeps an Outperform rating on the shares. The firm said they reported a solid 3Q, with revenue in-line and encouraging OpEx leverage. Overall volumes grew, though dermatology volumes were below estimates due to seasonality, and TissueCypher again demonstrated compelling momentum.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Castle Biosciences Inc (CSTL.O) is -8.97, compared to its 5-year average forward P/E of -29.12. For a more detailed relative valuation and DCF analysis to assess Castle Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-29.12

Current PE

-8.97

Overvalued PE

12.64

Undervalued PE

-70.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-22.21

Current EV/EBITDA

-42.73

Overvalued EV/EBITDA

10.21

Undervalued EV/EBITDA

-54.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

6.92

Current PS

1.97

Overvalued PS

13.26

Undervalued PS

0.59

Financials

Annual

Quarterly

FY2025Q2

YoY :

-0.94%

86.19M

Total Revenue

FY2025Q2

YoY :

-184.82%

-4.25M

Operating Profit

FY2025Q2

YoY :

-49.29%

4.52M

Net Income after Tax

FY2025Q2

YoY :

-51.61%

0.15

EPS - Diluted

FY2025Q2

YoY :

-38.42%

11.56M

Free Cash Flow

FY2025Q2

YoY :

-4.29%

77.27

Gross Profit Margin - %

FY2025Q2

YoY :

+42.43%

9.97

FCF Margin - %

FY2025Q2

YoY :

-48.78%

5.25

Net Margin - %

FY2025Q2

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 105.44% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

349.9K

USD

6-9

Months

2.5M

USD

0-12

Months

2.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

409.4K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

921.7K

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 105.44% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

349.9K

USD

6-9

Months

2.5M

USD

0-12

Months

2.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

CSTL News & Events

Events Timeline

2025-08-04 (ET)

2025-08-04

16:32:45

Castle Biosciences raises FY25 revenue view to $310M-$320M from $287M-$297M

2025-08-04

16:31:51

Castle Biosciences reports Q2 adjusted EPS 15c, consensus (50c)

2025-07-23 (ET)

2025-07-23

07:04:47

Castle Biosciences announces DecisionDx-Melanoma test granted BD designation

News

9.5

08-05Benzinga

Sterling Infrastructure Posts Better-Than-Expected Earnings, Joins Lemonade, DigitalOcean Holdings, Lattice Semiconductor And Other Big Stocks Moving Higher On Tuesday

9.5

08-05NASDAQ.COM

Castle (CSTL) Q2 Revenue Tops Estimates

9.5

08-04NASDAQ.COM

Castle Biosciences Inc. Reveals Decline In Q2 Bottom Line